ANB033, a Novel CD122 Antagonist in Development for the Treatment of Inflammatory and Autoimmune Diseases, Inhibited IL-15 and IL-2 Signaling in CD8+ and CD4+ T Cells In Vitro and in a Murine Model of GvHDJune 9, 2026Read article
Discovery of a Novel High Affinity Anti-Human CD122 Antagonist Monoclonal Antibody (ANB033) that Abrogates IL-2 and IL-15 Signaling for the Treatment of T Cell-Mediated Inflammatory and Autoimmune DiseasesJuly 19, 2023Read article
